PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
4.31%
Gross profit growth below 50% of AGEN's 19.89%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D growth less than half of AGEN's 37.16%. David Dodd would verify if efficiency advantage is sustainable.
-40.17%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-8.25%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Both companies reducing D&A. Martin Whitman would check industry patterns.
8.31%
EBITDA growth below 50% of AGEN's 17.12%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth 50-75% of AGEN's 15.23%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth above 1.5x AGEN's 3.05%. Michael Burry would check for concerning trends.
12.55%
Similar pre-tax income growth to AGEN's 12.12%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
12.55%
Similar net income growth to AGEN's 15.29%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
15.52%
EPS growth 50-75% of AGEN's 22.59%. Martin Whitman would scrutinize operations.
15.52%
Diluted EPS growth 50-75% of AGEN's 21.29%. Martin Whitman would scrutinize operations.
3.21%
Share count reduction exceeding 1.5x AGEN's 9.50%. David Dodd would verify capital allocation.
3.21%
Diluted share reduction exceeding 1.5x AGEN's 7.62%. David Dodd would verify capital allocation.